ストックスクリーナーアプリを入手
0.85
63.98%
-1.51
前日終値:
$2.36
開ける：
$0.9
24時間の取引高:
508
Relative Volume:
0.01
時価総額：
$12.87M
収益：
-
当期純損益:
$-4.74M
株価収益率:
-1.1333
EPS:
-0.75
ネットキャッシュフロー:
$-3.46M
1週間 パフォーマンス:
-63.98%
1か月 パフォーマンス:
-69.42%
6か月 パフォーマンス:
-72.76%
1年 パフォーマンス:
-76.39%
1日の値動き範囲:
$0.85
$0.90
1週間の範囲:
$0.90
$0.90
52週間の値動き範囲:
$0.90
$12.00
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
名前
Lipella Pharmaceuticals Inc
セクター
電話
412-901-0315
住所
400 N LEXINGTON ST, PITTSBURGH
LIPO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LIPO
Lipella Pharmaceuticals Inc
|
0.85 | 12.87M | 0 | -4.74M | -3.46M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.37 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
520.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.24 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.20 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.75 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipella Pharmaceuticals Inc (LIPO) 最新ニュース
Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology - GlobeNewswire
Lipella Pharmaceuticals announces U.S. patent issuance for diagnostic tech - TipRanks
New Patent Powers Lipella's Breakthrough: MRI Technology Could Transform Disease Detection Until 2045 - Stock Titan
Lipella Pharmaceuticals Announces 2025 Stockholders Meeting Date - TipRanks
LIPO Secures Continued Partnership with Cook MyoSite for Enhanced Product Development | LIPO Stock News - GuruFocus
Lipella Pharmaceuticals Inc. Re-Signs Manufacturing Collaboration Agreement with Cook MyoSite Inc. to Support LP-310 Clinical Development - MarketScreener
Lipella Re-Signs Manufacturing Collaboration Agreement with Cook MyoSite - Contract Pharma
Lipella Pharmaceuticals re-signs manufacturing collab with Cook MyoSite - TipRanks
Lipella Pharmaceuticals extends manufacturing pact with Cook MyoSite - Investing.com
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development - GlobeNewswire
First-Ever Oral Lichen Planus Treatment Advances as Lipella Secures Key Manufacturing Deal - Stock Titan
Lipella Pharmaceuticals to appeal Nasdaq noncompliance warningPittsburgh Business Times - The Business Journals
Lipella Pharmaceuticals Faces Nasdaq Compliance Challenge - TipRanks
LIPO: Lipella Pharmaceuticals Reports Promising Phase 2a Trial Results for LP-310 | LIPO Stock News - GuruFocus
Lipella Pharmaceuticals Presents Promising Phase 2a Trial Data - TipRanks
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 - GlobeNewswire
Breakthrough Phase 2a Data: New LP-310 Treatment Cuts Oral Lichen Planus Pain by 65%, Exceeds Endpoints - Stock Titan
Analytical Overview: Lipella Pharmaceuticals Inc (LIPO)’s Ratios Tell a Financial Story - DWinneX
Lipella Pharmaceuticals Abstract on Oral Lichen Planus - GlobeNewswire
Clinical Data: New Treatment Breakthrough for Oral Lichen PlanusPhase 2a Trial Shows Remarkable Improvement - Stock Titan
LIPO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
LIPO stock’s current quarter earnings estimates: What analysts predict? - uspostnews.com
Lipella Reports Positive Results from Second Cohort in LP-310 Phase 2a Trial for Oral Lichen Planus - Reuters
Lipella Pharmaceuticals announces results from second cohort of LP-310 trial - TipRanks
Lipella Reports Positive Phase 2a Results from Second - GlobeNewswire
Clinical Trial Breakthrough: New Oral Lichen Planus Treatment Shows 65% Pain Reduction, Multiple Endpoint Success - Stock Titan
Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis - MarketBeat
Lipella Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Canada
Lipella Pharmaceuticals regains Nasdaq compliance - Investing.com Australia
Lipella Pharmaceuticals expands preferred stock class - Investing.com Australia
Lipella Pharmaceuticals stock hits 52-week low at $2 By Investing.com - Investing.com Canada
Lipella Pharmaceuticals expands preferred stock class By Investing.com - Investing.com South Africa
Lipella Pharmaceuticals stock hits 52-week low at $2 - Investing.com
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus - The Manila Times
Clinical Trial Success: Lipella's Novel OLP Treatment Shows Encouraging Results in Phase 2a Study - Stock Titan
Virtu Financial LLC Acquires Shares of 13,310 Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) - Defense World
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast - The Globe and Mail
Clinical Trial Success: Lipella's 40-Year Veteran Shares Breakthrough Journey in Exclusive Interview - Stock Titan
Tariffs and Tech Troubles Weigh on Markets - The Globe and Mail
Lipella Pharmaceuticals Inc. (LIPO) reports earnings - Quartz
LIPELLA PHARMACEUTICALS INC. SEC 10-K Report - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Spartan Capital Securities, LLC Proudly Serves as the Sole Agent in Lipella Pharmaceuticals Inc. - Ukraine Business Journal
Lipella Pharmaceuticals stock hits 52-week low at $2.21 - Investing.com Australia
Spartan Capital Securities, LLC Announces Key February Transactions - The Manila Times
Spartan Capital Securities, LLC Announces Key February Transactions - GlobeNewswire Inc.
Lipella Pharmaceuticals Inc (LIPO) 財務データ
収益
当期純利益
現金流量
EPS
0.20%
1.12%
大文字化:
|
ボリューム (24 時間):